Skye Bioscience Inc.’s Post

Join our webinar tomorrow at 3:00 PM to see how Aruna Bio is making revolutionary steps by developing therapeutics to help stroke victims reduce inflammation in their brains caused by a stroke. https://hubs.la/Q02sgLmS0

Did you register already? Link below

Today's Paper of the Day is on carbon monoxide poisoning: from microbes to therapeutics https://lnkd.in/ddmA2hyy Join us to read 1 paper per day and stay up-to-date as we cover the spectrum of critical care across 2024

Geographic Atrophy 101 with Dr. Deepak Sambhara Geographic Atrophy represents the final stage of dry age-related macular degeneration which is an eye condition that impacts the macula of the #retina, significantly affecting your central vision, which is what you see directly in front of you. However, your peripheral vision, or what you can see to the sides, remains intact. While the exact causes of the eye changes leading to geographic atrophy remain uncertain, researchers believe that a part of the immune system known as the complement cascade is involved. In this video, Dr. Sambhara explains how the complement cascade works and how recent therapies for #GA aim to slow down the progression of this disease. Financial Disclosures: Apellis Pharmaceuticals Eclipse Life Sciences, Genentech Iveric Bio, An Astellas Company Regeneron #GA #geographicastrophy #AMD #maculardegeneration #eyehealth #inflammation #complementcascade

Unlock the truth behind Peptides and Human Cellular Tissue Products in this comprehensive virtual masterclass. Get ready to revolutionize your practice with the All Things Peptides Virtual Masterclass! Happening June 7-8, this event is packed with insights, strategies, and practical applications in peptides and advanced biologics. Why Attend? * Access Recordings: Can’t make it live? All ticket holders get access to recordings of all sessions, presentation slides, and event materials. * Comprehensive Knowledge: Dive deep into peptides and advanced biologics with practical implementation strategies. * Empowerment & Growth: MedMasters aims to educate and empower you with resources to deliver superior therapies, revolutionizing patient outcomes and opening doors to new revenue streams. Don’t miss out! Secure your spot now and elevate your practice. Learn More: https://lnkd.in/ecQzyDFM

This week, we're at the TD Cowen 44th Annual Health Care Conference. We kicked off the morning with Nathan Dowden, President and Chief Operating Officer, who joined Joseph Thome, PhD, Managing Director, Senior Biotechnology Equity Research Analyst at TD Cowen, on the Orphan Bone & Neuromuscular Diseases panel. Nate highlighted our pipeline of intracellular therapeutics and the important progress we have made across our neuromuscular therapeutic areas.    Here are just a few of our 2024 highlights: · Cash runway: through the second quarter 2026 · ENTR-601-44 (DMD exon 44): readout of our Phase 1 healthy normal volunteer data in the second half of 2024 · ENTR-601-45 (DMD exon 45): regulatory filing to initiate a multiple ascending dose trial in the fourth quarter 2024 · VX-670 (partnered DM1 program with Vertex): ongoing Phase 1/2 multiple ascending dose trial in DM1 patients   If you missed the panel, the replay is available here: https://lnkd.in/e6_UBk-n. Our Corporate Presentation is also available here: https://lnkd.in/e4eBUv5i   #InvestorRelations #Biotech

🔬 A recent study in EHP Publishing identified a comprehensive set of over 900 chemicals potentially associated with an increased risk of breast cancer. We took a closer look and found that: 👉 189 out of these 921 breast cancer-relevant chemicals have been measured in food contact articles. 👉 75% of those breast cancer-relevant food contact chemicals were detected in plastics, but all material groups (with the exception of glass) contained some of the chemicals. 👉 A more comprehensive approach to chemical testing is needed to ensure the safety of consumer products. Read a detailed summary of the study and our analysis ➡️ https://lnkd.in/d5cwsmrU

Join our webinar on April 17th at 3:00 PM to see how Aruna Bio is making revolutionary steps by developing therapeutics to help stroke victims reduce inflammation in their brains caused by a stroke. https://hubs.la/Q02sh0Pr0

Overcoming preclinical hurdles is a big topic in the oncology drug development space. Bispecific antibodies (BsAbs) is a promising frontier in targeted cancer therapies, yet the journey from concept to clinic is fraught with many challenges. Unfortunately, only about 10-15% of BsAB drugs successfully make it to the clinic. A significant portion of these failures can be attributed to the inadequacies of preclinical models that fail to predict clinical outcomes accurately. Selecting appropriate preclinical models is paramount because they provide essential insights into the drug's efficacy and safety profile. In this white paper, we discuss the rising importance of BsAbs as anti-cancer drugs, while emphasizing the importance of implementing an integrated suite of preclinical solutions to accelerate the development of BsAb candidates. A case study of HanX’s BsAb, HX009, is presented to highlight the integrated selection of in vitro and in vivo preclinical solutions used to comprehensively characterize this innovative BsAb. Importantly, these studies were instrumental in supporting the clearance of the company’s IND application submitted to the FDA. At Crown Bioscience, we understand these challenges all too well. By leveraging our integrated solutions approach, combining cutting-edge technology with deep expertise, researchers can enhance the predictability of their preclinical trials, reducing the risk of late-stage failures and accelerating the development of life-saving therapies. #oncology #BsAbs #BispecificAntibodies #DrugDevelopment #PreclinicalModels  https://lnkd.in/dzZg36zA

A big day at Juvena Therapeutics, as their lead candidate, JUV-161, has received positive FDA feedback and Orphan Disease Designation (ODD) for the treatment of Myotonic Dystrophy Type 1 (DM1). This is a major win for the broader ecosystem as an example of how founder-led biotech can truly change how we think of addressing unmet medical needs. As an early investor, I take immense pride in the team's dedicated efforts over the course of five and a half years, involving hard work and determination, to establish a world-class, fully integrated platform for the discovery and development of biologics. Their unique approach to repairing and restoring muscle health with a biologic that enhances muscle regeneration, metabolism, and function, countering the effects of aging and degenerative disease. Congrats Hanadie Yousef, Jeremy O'Connell, Neil Berkley, Mo Tabrizi, all the scientists, biologists, engineers, rest of the team, other investors, and the many partners who have believed in this group. Big things ahead!!! 🚀 Link to the announcement: https://lnkd.in/gvRTC2NS #biotech #venturecapital #founderled #healthcare #MyotonicDystrophy #RareDisease #unmetmedicalneed #healthspan #sarcopenia